Back to top
more

InMed Pharmaceuticals (INM)

(Delayed Data from NSDQ)

$0.25 USD

0.25
616,697

-0.05 (-16.83%)

Updated Apr 25, 2024 03:59 PM ET

After-Market: $0.25 0.00 (-0.79%) 6:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for INM

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

InMed Pharmaceuticals Inc. [INM]

Reports for Purchase

Showing records 1 - 20 ( 31 total )

Company: InMed Pharmaceuticals Inc.

Industry: Medical - Drugs

Record: 1

02/27/2023

Company Report

Pages: 4

Dropping Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: InMed Pharmaceuticals Inc.

Industry: Medical - Drugs

Record: 2

10/17/2022

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: InMed Pharmaceuticals Inc.

Industry: Medical - Drugs

Record: 3

10/14/2022

Company Report

Pages: 4

Dropping Coverage

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 5.00

Research Provided by a Third Party

Company: InMed Pharmaceuticals Inc.

Industry: Medical - Drugs

Record: 4

06/17/2022

Company Report

Pages: 3

THCV launch expands rare cannabinoids portfolio

Provider: Edison Investment Research Limited

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: InMed Pharmaceuticals Inc.

Industry: Medical - Drugs

Record: 5

05/31/2022

Company Report

Pages: 3

Health and wellness product launches

Provider: Edison Investment Research Limited

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: InMed Pharmaceuticals Inc.

Industry: Medical - Drugs

Record: 6

05/31/2022

Company Report

Pages: 3

Health and wellness product launches

Provider: Edison Investment Research Limited

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: InMed Pharmaceuticals Inc.

Industry: Medical - Drugs

Record: 7

05/16/2022

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: InMed Pharmaceuticals Inc.

Industry: Medical - Drugs

Record: 8

05/13/2022

Company Report

Pages: 8

FY3Q22 Recap - Waiting for Visibility into Commercial Ops

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 12.50

Research Provided by a Third Party

Company: InMed Pharmaceuticals Inc.

Industry: Medical - Drugs

Record: 9

05/03/2022

Company Report

Pages: 19

Notable launches of high-value rare cannabinoids

Provider: Edison Investment Research Limited

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: InMed Pharmaceuticals Inc.

Industry: Medical - Drugs

Record: 10

02/16/2022

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: InMed Pharmaceuticals Inc.

Industry: Medical - Drugs

Record: 11

02/16/2022

Company Report

Pages: 2

Generating commercial sales of CBC and CBT

Provider: Edison Investment Research Limited

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: InMed Pharmaceuticals Inc.

Industry: Medical - Drugs

Record: 12

02/15/2022

Company Report

Pages: 8

FY2Q22 Recap - Revenues Arrive

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 12.50

Research Provided by a Third Party

Company: InMed Pharmaceuticals Inc.

Industry: Medical - Drugs

Record: 13

11/29/2021

Company Report

Pages: 44

Charging After Pharmaceutical-Grade Cannabinoids; Initiating at Buy and $6 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 50.00

Research Provided by a Third Party

Company: InMed Pharmaceuticals Inc.

Industry: Medical - Drugs

Record: 14

11/19/2021

Company Report

Pages: 8

FY1Q22 Recap - Pipeline on Track with Near-term Revenues

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 12.50

Research Provided by a Third Party

Company: InMed Pharmaceuticals Inc.

Industry: Medical - Drugs

Record: 15

11/19/2021

Daily Note

Pages: 5

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: InMed Pharmaceuticals Inc.

Industry: Medical - Drugs

Record: 16

11/17/2021

Company Report

Pages: 6

Progress across the business

Provider: Edison Investment Research Limited

Analyst: JACOBS M

Price: 12.50

Research Provided by a Third Party

Company: InMed Pharmaceuticals Inc.

Industry: Medical - Drugs

Record: 17

09/29/2021

Company Report

Pages: 8

FY4Q21 Recap - Revenues on the Way

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: InMed Pharmaceuticals Inc.

Industry: Medical - Drugs

Record: 18

09/29/2021

Company Report

Pages: 5

INM-755 Phase II about to begin

Provider: Edison Investment Research Limited

Analyst: JACOBS M

Price: .00

Research Provided by a Third Party

Company: InMed Pharmaceuticals Inc.

Industry: Medical - Drugs

Record: 19

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for INM

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: InMed Pharmaceuticals Inc.

Industry: Medical - Drugs

Record: 20

09/20/2021

Company Report

Pages: 6

Acquiring BayMedica

Provider: Edison Investment Research Limited

Analyst: JACOBS M

Price: .00

Research Provided by a Third Party